Q1 2024 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2024-05-13 · accession 0001727492-24-000006
$378.3M
Reported value
12
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $152.8M | 40.4% | 10,360,945 | Common | SOLE |
| 016259202 | — | ALIMERA SCIENCES INC | $65.7M | 17.4% | 16,835,154 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $36.5M | 9.64% | 1,435,993 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $26.4M | 6.99% | 1,888,881 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $26.1M | 6.90% | 1,100,730 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $20.9M | 5.51% | 1,296,447 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $15.0M | 3.96% | 858,070 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $14.2M | 3.75% | 484,711 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $9.5M | 2.52% | 587,276 | Common | SOLE |
| 69012T305 | OTLK | OUTLOOK THERAPEUTICS INC | $6.0M | 1.58% | 500,000 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $3.9M | 1.02% | 758,502 | Common | SOLE |
| 44975P103 | NBP | I MAB | $1.4M | 0.37% | 756,538 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.